Gawron-Gzella Anna, Marek Paulina, Chanaj Justyna, Matławska Irena
Department of Pharmacognosy, Poznań University of Medical Sciences, Swiecickiego 4, 60-781 Poznań, Poland.
Acta Pol Pharm. 2010 Jul-Aug;67(4):335-43.
Abstract: Chromatography (TLC and HPLC) tests were performed of 11 preparations containing dry extract of Ginkgo biloba leaves: three pharmaceuticals (preparations 1, 3 and 5) and eight dietary supplements (preparations 2, 4, 6-11), and dry extract of Ginkgo biloba leaves (preparation 12) as a standard certified for compliance with Eur. Ph. 6.1. and FP VIII (1, 2). Preparations registered in Poland as pharmaceuticals contained the major active ingredients (flavonoids and terpene lactones) in amount declared by their producers (and consistent with pharmacopoeial requirements) and acceptable level of potentially toxic ginkgolic acids (below 5 ppm). The concentration of active compounds in dietary supplements was varied. Some of them satisfied applicable quality criteria (mainly preparation 8), however, the majority had reduced levels of therapeutic compounds (4, 6, 7, 11) and increased concentration of ginkgolic acids (4, 9, 10, 11).
对11种含有银杏叶干提取物的制剂进行了色谱分析（薄层色谱法和高效液相色谱法）：3种药品（制剂1、3和5）、8种膳食补充剂（制剂2、4、6 - 11）以及作为符合欧洲药典6.1版和法国药典VIII（1, 2）标准认证的银杏叶干提取物（制剂12）。在波兰注册为药品的制剂所含主要活性成分（黄酮类化合物和萜类内酯）的量与其生产商宣称的一致（且符合药典要求），并且潜在有毒银杏酸的含量处于可接受水平（低于5 ppm）。膳食补充剂中活性化合物的浓度各不相同。其中一些符合适用的质量标准（主要是制剂8），然而，大多数制剂的治疗性化合物含量降低（4、6、7、11），银杏酸浓度升高（4、9、10、11）。
